Emicizumab-话题@MedSci

#Emicizumab#

13篇内容 | 1316人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1464083, encodeId=64fe14640834a, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, objectType=article, longId=292247, objectId=bce929224e89, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bce929224e89, replyNumber=0, likeNumber=74, createdTime=2021-12-21, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bce929224e89, moduleTitle=Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bce929224e89)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464082, encodeId=bc4d1464082a5, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Blood：Emicizumab治疗获得性血友病A, objectType=article, longId=199478, objectId=3c8b1994e856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c8b1994e856, replyNumber=0, likeNumber=79, createdTime=2020-08-16, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c8b1994e856, moduleTitle=Blood：Emicizumab治疗获得性血友病A, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c8b1994e856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464081, encodeId=8d4b1464081cd, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Blood：评估Emicizumab功能的新模型！, objectType=article, longId=194665, objectId=6b8a19466578, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b8a19466578, replyNumber=0, likeNumber=104, createdTime=2020-05-25, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b8a19466578, moduleTitle=Blood：评估Emicizumab功能的新模型！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b8a19466578)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464080, encodeId=ab8f1464080bb, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Blood：Emicizumab预防用于儿童A型血友病, objectType=article, longId=181209, objectId=7d9b18120992, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d9b18120992, replyNumber=0, likeNumber=93, createdTime=2019-10-16, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d9b18120992, moduleTitle=Blood：Emicizumab预防用于儿童A型血友病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d9b18120992)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464079, encodeId=b0bb14640e9b3, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, objectType=article, longId=175129, objectId=21e61e5129ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=21e61e5129ae, replyNumber=0, likeNumber=72, createdTime=2019-07-12, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=21e61e5129ae, moduleTitle=2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=21e61e5129ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464078, encodeId=c62e14640e85e, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性, objectType=article, longId=165179, objectId=f5ca1651e910, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ca1651e910, replyNumber=0, likeNumber=90, createdTime=2019-04-30, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ca1651e910, moduleTitle=Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ca1651e910)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464077, encodeId=a2a514640e7f7, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=Lancet Haematol：Emicizumab用于A型血友病出血预防, objectType=article, longId=164518, objectId=97741645181b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97741645181b, replyNumber=0, likeNumber=69, createdTime=2019-04-19, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97741645181b, moduleTitle=Lancet Haematol：Emicizumab用于A型血友病出血预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97741645181b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464076, encodeId=71d314640e68a, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=血友病进口特效药Emicizumab上市价格高达百万, objectType=article, longId=155369, objectId=c33115536945, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c33115536945, replyNumber=0, likeNumber=87, createdTime=2018-12-09, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c33115536945, moduleTitle=血友病进口特效药Emicizumab上市价格高达百万, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c33115536945)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464075, encodeId=2ea814640e5f4, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=NEJM：Emicizumab用于预防A型血友病患者出血, objectType=article, longId=147773, objectId=aadd14e7739a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aadd14e7739a, replyNumber=0, likeNumber=80, createdTime=2018-09-01, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aadd14e7739a, moduleTitle=NEJM：Emicizumab用于预防A型血友病患者出血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aadd14e7739a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464074, encodeId=085a14640e4f5, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=罗氏公司的emicizumab在英国提前获批, objectType=article, longId=125752, objectId=40a3125e529c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40a3125e529c, replyNumber=0, likeNumber=66, createdTime=2018-01-07, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40a3125e529c, moduleTitle=罗氏公司的emicizumab在英国提前获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40a3125e529c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464073, encodeId=bf5114640e3b3, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=NEJM：emicizumab可降低体内出现抑制剂的A型血友病患者87%出血事件的发生率！, objectType=article, longId=105412, objectId=c52a105412b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c52a105412b0, replyNumber=0, likeNumber=75, createdTime=2017-07-15, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c52a105412b0, moduleTitle=NEJM：emicizumab可降低体内出现抑制剂的A型血友病患者87%出血事件的发生率！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c52a105412b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464072, encodeId=a4cb14640e25b, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, objectType=article, longId=85803, objectId=b71585803c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b71585803c3, replyNumber=0, likeNumber=70, createdTime=2016-12-29, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b71585803c3, moduleTitle=罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b71585803c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1464071, encodeId=067d14640e1af, content=<a href='/topic/show?id=a2566e25ba' target=_blank style='color:#2F92EE;'>#Emicizumab#</a>, objectTitle=NEJM：Emicizumab可明显降低重症血友病A患者的出血率, objectType=article, longId=69266, objectId=7c0d692663a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c0d692663a, replyNumber=0, likeNumber=86, createdTime=2016-05-27, rootId=0, userName=by2011, userId=aaea6584343, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c0d692663a, moduleTitle=NEJM：Emicizumab可明显降低重症血友病A患者的出血率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c0d692663a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Emicizumab

2020-05-29

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Haemophilia：使用与不使用 FVIII 抑制剂的重度 A 型血友病儿童患者中 emicizumab 预防的耐受性和安全性的真实世界经验

2021-12-21

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Blood：Emicizumab治疗获得性血友病A

2020-08-16

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Blood：评估Emicizumab功能的新模型！

2020-05-25

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Blood：Emicizumab预防用于儿童A型血友病

2019-10-16

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

2019年国际血栓和止血学会：罗氏艾美赛珠单抗（Emicizumab）在III期研究中再次证明了安全性

2019-07-12

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Lancet haemat：A型血友病患者采用emicizumab预防出血的效果和安全性

2019-04-30

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

Lancet Haematol：Emicizumab用于A型血友病出血预防

2019-04-19

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

血友病进口特效药Emicizumab上市价格高达百万

2018-12-09

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

NEJM：Emicizumab用于预防A型血友病患者出血

2018-09-01

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

罗氏公司的emicizumab在英国提前获批

2018-01-07

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

NEJM：emicizumab可降低体内出现抑制剂的A型血友病患者87%出血事件的发生率！

2017-07-15

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

罗氏A型血液病预防性治疗药物emicizumabIII期临床获得成功

2016-12-29

by2011 (审核中...)

前往app查看评论内容

#Emicizumab#

NEJM：Emicizumab可明显降低重症血友病A患者的出血率

2016-05-27

科室
- - 订阅+
  - 更多科室
工具
服务